Fiche société
Shanghai Zhimeng Biopharma, Inc.
Traitements, essais et publications liés.
Traitements6programmes
Essais2liés
Publications10liées
SourceDBlocale
Traitements
6| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| Test drug CB03-154 10mg groupCB03-154 is an investigational drug developed by Shanghai Zhimeng Biopharma Inc. for the treatment of Focal Epilepsy. | Épilepsie, Sclérose latérale amyotrophique | Phase 2/3 | À vérifier | China | À vérifier |
| Test drug CB03-154 15mg groupDescription non affichée : incohérence de maladie détectée. Consultez l’essai clinique officiel associé. | Sclérose latérale amyotrophique | Phase 2/3 | Ralentissement de la progression + Traitement symptomatique | China | À vérifier |
| Test drug CB03-154 20mg groupCB03-154 is an investigational drug developed by Shanghai Zhimeng Biopharma Inc. for the treatment of Focal Epilepsy. | Épilepsie | Phase 2 | À vérifier | Australia | À vérifier |
| Test drug CB03-154 5mg groupCB03-154 is an investigational drug developed by Shanghai Zhimeng Biopharma Inc. for the treatment of Focal Epilepsy. | Épilepsie, Sclérose latérale amyotrophique | Phase 2/3 | À vérifier | China | À vérifier |
| Test drug CB03-154 5mg groupCB03-154 is an investigational drug developed by Shanghai Zhimeng Biopharma Inc. for the treatment of Focal Epilepsy. | Épilepsie | Phase 2 | À vérifier | Australia | À vérifier |
| Test drug CB03-154 5mg groupCB03-154 is an investigational drug developed by Shanghai Zhimeng Biopharma Inc. for the treatment of Focal Epilepsy. | Sclérose latérale amyotrophique | Phase 2/3 | À vérifier | China | À vérifier |
Essais cliniques
2| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Test drug CB03-154 5mg group | Sclérose latérale amyotrophique | Phase 2/3 | NCT07082192 | A Study to Evaluate the Efficacy and Safety of Different Doses of CB03-154 in Adult Patients With Amyotrophic Lateral Sclerosis (ALS) | RECRUITING |
| Test drug CB03-154 5mg group | Épilepsie | Phase 2 | NCT06612775 | A Study to Evaluate the Safety, Tolerability, and Efficacy of CB03-154 in Adult Patients With Focal Epilepsy | RECRUITING |
Publications
10| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| Test drug CB03-154 15mg group | Ameliorative effects of half-dose saffron and chamomile combination on Psycho-endocrinological changes in a diabetic murine model. | PloS one | ||
| Test drug CB03-154 15mg group | A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Novel Intravenous Formulation of Meloxicam (QP001) in Healthy Chinese Subjects. | Drug design, development and therapy | ||
| Test drug CB03-154 15mg group | Accessing the efficacy and peri-operative adverse effects of three different hyperbaric bupivacaine 0.5% dosages for spinal anesthesia induction in lower limb orthopedic surgeries: a randomized clinical trial. | BMC anesthesiology | ||
| Test drug CB03-154 5mg group | Minimum effective low dose of antithymocyte globulin in people aged 5-25 years with recent-onset stage 3 type 1 diabetes (MELD-ATG): a phase 2, multicentre, double-blind, randomised, placebo-controlled, adaptive dose-ranging trial. | Lancet (London, England) | ||
| Test drug CB03-154 5mg group | Safety, Tolerability, and Pharmacokinetics of Mufemilast, a PDE4 Inhibitor, in Healthy Participants: A First-in-Human Phase 1 Study. | Clinical pharmacology in drug development | ||
| Test drug CB03-154 5mg group | Use of pre-operative Midazolam as oral sedation for anxiety reduction amongst patients scheduled for dental extractions under local anaesthesia. | JPMA. The Journal of the Pakistan Medical Association | ||
| Test drug CB03-154 10mg group | Prefrontal cortex-nucleus reuniens-hippocampus network exhibits sex-differentiated responses to stress and antidepressant treatment in rats. | Psychopharmacology | ||
| Test drug CB03-154 10mg group | Unprecedented in vivo activity of telacebec against Mycobacterium leprae. | PLoS neglected tropical diseases | ||
| Test drug CB03-154 10mg group | Bioequivalence Study of Two Empagliflozin Tablets in Healthy Chinese Subjects Under Fasting and Fed Conditions. | Clinical pharmacology in drug development | ||
| Test drug CB03-154 10mg group | Exercise treadmill testing for efficacy evaluation in randomized, controlled trials. | American heart journal |